Barclays PLC lowered its position in shares of Crispr Therapeutics AG (NASDAQ:CRSP) by 61.7% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,309 shares of the company’s stock after selling 8,568 shares during the period. Barclays PLC’s holdings in Crispr Therapeutics were worth $324,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. ARK Investment Management LLC boosted its position in Crispr Therapeutics by 6.3% during the 4th quarter. ARK Investment Management LLC now owns 2,956,635 shares of the company’s stock valued at $180,074,000 after buying an additional 174,495 shares during the period. Farmers & Merchants Trust Co of Chambersburg PA purchased a new stake in Crispr Therapeutics during the 4th quarter valued at $26,000. Capital Advisors Inc. OK boosted its position in Crispr Therapeutics by 9.4% during the 4th quarter. Capital Advisors Inc. OK now owns 127,029 shares of the company’s stock valued at $7,737,000 after buying an additional 10,872 shares during the period. State Street Corp boosted its position in Crispr Therapeutics by 2.1% during the 3rd quarter. State Street Corp now owns 37,103 shares of the company’s stock valued at $1,521,000 after buying an additional 758 shares during the period. Finally, Webster Bank N. A. purchased a new stake in Crispr Therapeutics during the 4th quarter valued at $26,000. 52.04% of the stock is owned by institutional investors and hedge funds.
Shares of Crispr Therapeutics stock opened at $33.68 on Tuesday. The company has a 50-day moving average of $51.39 and a 200 day moving average of $53.21. The firm has a market cap of $2.32 billion, a price-to-earnings ratio of 34.72 and a beta of 2.74. Crispr Therapeutics AG has a 1 year low of $32.30 and a 1 year high of $74.00.
Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Wednesday, February 12th. The company reported $0.51 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.68) by $1.19. The company had revenue of $77.00 million during the quarter, compared to analyst estimates of $39.08 million. Crispr Therapeutics had a net margin of 23.09% and a return on equity of 11.74%. Crispr Therapeutics’s quarterly revenue was up 76900.0% compared to the same quarter last year. During the same period last year, the business earned ($0.92) EPS. Equities analysts anticipate that Crispr Therapeutics AG will post -4.54 EPS for the current fiscal year.
CRSP has been the subject of several research reports. Wells Fargo & Co restated a “buy” rating on shares of Crispr Therapeutics in a report on Friday, December 6th. Piper Jaffray Companies restated a “buy” rating and issued a $104.00 price objective on shares of Crispr Therapeutics in a report on Monday, December 16th. Citigroup upped their price objective on shares of Crispr Therapeutics from $28.00 to $31.00 and gave the stock a “sell” rating in a report on Wednesday, March 4th. Canaccord Genuity upped their price objective on shares of Crispr Therapeutics from $72.00 to $80.00 and gave the stock a “positive” rating in a report on Wednesday, November 20th. Finally, Roth Capital upped their price objective on shares of Crispr Therapeutics from $65.00 to $100.00 in a report on Tuesday, November 19th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and thirteen have assigned a buy rating to the stock. Crispr Therapeutics presently has an average rating of “Buy” and an average target price of $73.04.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Further Reading: What are momentum indicators and what do they show?
Want to see what other hedge funds are holding CRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Crispr Therapeutics AG (NASDAQ:CRSP).
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.